investors.alnylam.com
Alnylam Pharmaceuticals, Inc. - Financial Statements
http://investors.alnylam.com/financials-statements.cfm
Delivery of RNAi Therapeutics. Hepatitis B Virus Infection. Beta-Thalassemia and Iron Overload Disorders. Alnylam to Present New Clinical Results at 58th Annual Meeting of the American Society of Hematology (ASH). Alnylam Pharmaceuticals Reports Third Quarter 2016 Financial Results and Highlights Recent Period Activity. Alnylam to Webcast Presentations at Upcoming November Investor Conferences. Data as of 11:22 AM ET on 11.03.2016. Minimum 20 Minute Delay.
investors.alnylam.com
Alnylam Pharmaceuticals, Inc. - Overview
http://investors.alnylam.com/overview.cfm
Delivery of RNAi Therapeutics. Hepatitis B Virus Infection. Beta-Thalassemia and Iron Overload Disorders. Nature, Nature Medicine, Nature Biotechnology, Cell, New England Journal of Medicine,. Founded in 2002, Alnylam maintains headquarters in Cambridge, Massachusetts. For more information, please visit www.alnylam.com. Alnylam to Present New Clinical Results at 58th Annual Meeting of the American Society of Hematology (ASH). Alnylam to Webcast Presentations at Upcoming November Investor Conferences.
investors.alnylam.com
Alnylam Pharmaceuticals, Inc. - Shareholder Briefcase Registration
http://investors.alnylam.com/briefcase.cfm
Delivery of RNAi Therapeutics. Hepatitis B Virus Infection. Beta-Thalassemia and Iron Overload Disorders. Collect, zip and download files from our Investor Relations website. Click on the briefcase icon. Located near most downloadable files throughout our IR website and use this page to manage your briefcase. Please fill in the form below to access this feature. *. Fixed Income Analyst (sell-side). Fixed Income Analyst (buy-side). Portfolio Manager (Fixed Income). Type in number *. Minimum 20 Minute Delay.
espenshadelab.org
People : Espenshade Lab
http://espenshadelab.org/people
L-R): Jiwon Hwang, Sara Clasen, Peter Espenshade (back), Risa Burr, Cezar Stoica, Meredith McGuire (front), He Gu, Shan Zhao, Wei Shao. Peter J. Espenshade, Ph.D. Professor and Associate Dean for Graduate Biomedical Education. Wei Shao, Ph.D. Jiwon Hwang, Ph.D. Cezar Stoica, Ph.D. Graduate student, BCMB program. Graduate student, BCMB program. Graduate student, BCMB program. He (鹤) graduated from Tsinghua University in Beijing, China with a Bachelor of Science in Biology. There, in the lab of Dr....That ...
amyloidosis.org.uk
ATTR Amyloidosis - Amyloidosis Patient Information SiteAmyloidosis Patient Information Site
http://www.amyloidosis.org.uk/introduction-to-attr-amyloidosis
Amyloidosis Patient Information Site. Nomenclature what’s in a name? About the National Amyloidosis Centre. Patient and public involvement. Symptoms and Signs of AL Amyloidosis. Investigations for AL Amyloidosis. Treatment of AL Amyloidosis. Troubleshooting for patients with AL Amyloidosis. Introduction to AA Amyloidosis. Diagnosis of AA amyloidosis. Treatment of AA Amyloidosis. Diagnosis of Cardiac Amyloidosis. Treatment of Cardiac Amyloidosis. Other Types of Amyloidosis. SAP scintigraphy (SAP scan).
obeposition.blogspot.com
Obesity: June 2011
http://obeposition.blogspot.com/2011_06_01_archive.html
Blog, news, companies, Body Mass Index, BMI, weight loss, obese, adjustable gastric lap-band surgery, Weight Management, Nutritional, overweight. Pharmaceuticals Search Engine [selected websites]. VIVUS : Additional Data From QNEXA Clinical Trials. EndoSphere : Patent for Obesity Treatment. Boehringer Ingelheim and Zealand Pharma : licence . Regulus Therapeutics and Alnylam Pharmaceuticals :. New GE Technology Targets Obesity-related Disease. Thursday, June 30, 2011. Prevention of Progression to Diabetes.
cambridgechamber.org
Economic Overview
http://www.cambridgechamber.org/business/economic.html
Cambridge, Massachusetts is commonly referred to as the most entrepreneurial place on earth. More than 105,000 people are employed by Cambridges nearly 5,300 businesses, in fields such as professional services, health care, R&D, technology, and the citys over 150 nonprofit and social service agencies. Cambridge has established itself as the epicenter of the worlds life sciences industry, currently hosting over 125 biotechnology companies. Johnson and Johnson, Takeda. Employ more than 10,000 people. S lar...
bleedingdisorder.wordpress.com
Alnylam and Collaborators Publish Pre-clinical Study Results in Nature Medicine on ALN-AT3 | Bringing Generations Together
https://bleedingdisorder.wordpress.com/2015/04/14/alnylam-and-collaborators-publish-pre-clinical-study-results-in-nature-medicine-on-aln-at3
The old and the young have to learn from each other. Symptomatic Carriers of Hemophilia. Von Willebrand Disease (vWD) FAQ. Strategic Summit on Von Willebrand Disease. In a Phase 3 Trial, Zonovate Provided Long-term Efficacy and Safety in the Prophylaxis and Treatment of Bleeds in People with Haemophilia A. Alnylam and Collaborators Publish Pre-clinical Study Results in Nature Medicine on ALN-AT3. April 14, 2015. CAMBRIDGE, Mass.–(BUSINESS WIRE)–. Sehgal et al., Nat Med,. Doi:10.1038/nm.3847),. Founded in...
investors.alnylam.com
Alnylam Pharmaceuticals, Inc. - Stock Information
http://investors.alnylam.com/stockquote.cfm
Delivery of RNAi Therapeutics. Hepatitis B Virus Infection. Beta-Thalassemia and Iron Overload Disorders. Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY). 12:03 PM ET on 08.19.2016. Sign up for e-mail alerts. Alnylam Completes Enrollment in ENDEAVOUR Phase 3 Study with Revusiran, an Investigational RNAi Therapeutic for Patients with Hereditary ATTR Amyloidosis with Cardiomyopathy (hATTR-CM). Alnylam Pharmaceuticals Reports Second Quarter 2016 Financial Results and Highlights Recent Period Progress.
SOCIAL ENGAGEMENT